Alendronate for Effective Treatment of Male Osteoporosis : An Insight

被引:0
作者
Al Lawati, Hanan [1 ]
Al Busaidi, Sara [2 ]
Al Rawahi, Thuraiya [3 ]
Al Lawati, Abdullah [4 ]
Kifah, Ahmed [5 ]
Das, Srijit [6 ]
机构
[1] Oman Coll Hlth Sci, Dept Pharmaceut, Pharm Program, Muscat, Oman
[2] Sultan Qaboos Univ, Muscat, Oman
[3] Royal Coll Surg Ireland Bahrain, Muharraq, Bahrain
[4] Sultan Qaboos Univ Hosp, Muscat, Oman
[5] Natl Univ, Sohar, Oman
[6] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Human & Clin Anat, Muscat, Oman
关键词
Alendronate; drug; osteoporosis; male; skeletal; bone; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE RISK; ZOLEDRONIC ACID; PARATHYROID-HORMONE; DOUBLE-BLIND; IN-VITRO; BISPHOSPHONATES; MEN; WOMEN; PREVALENCE;
D O I
10.2174/0113816128310838240820065324
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing phosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 141 条
  • [21] Bone mineral density reference values in Singaporean adults and comparisons for osteoporosis establishment - The Yishun Study
    Chen, Kexun Kenneth
    Wee, Shiou-Liang
    Pang, Benedict Wei Jun
    Lau, Lay Khoon
    Jabbar, Khalid Abdul
    Seah, Wei Ting
    Srinivasan, Sivasubramanian
    Jagadish, Mallya Ullal
    Ng, Tze Pin
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2020, 21 (01)
  • [22] Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid
    Chennuru, S.
    Koduri, J.
    Baumann, M. A.
    [J]. INTERNAL MEDICINE JOURNAL, 2008, 38 (08) : 635 - 637
  • [23] CHESNUT CH, 1993, OSTEOPOROSIS INT, V3, pS17
  • [24] Pharmacokinetics of intravenous alendronate
    Cocquyt, V
    Kline, WF
    Gertz, BJ
    Van Belle, SJP
    Holland, SD
    DeSmet, M
    Quan, H
    Vyas, KP
    Zhang, KYE
    De Grève, J
    Porras, AG
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (04) : 385 - 393
  • [25] Bone mass in middle-aged osteoporotic men and their relatives: Familial effect
    Cohen-Solal, ME
    Baudoin, C
    Omouri, M
    Kuntz, D
    De Vernejoul, MC
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (12) : 1909 - 1914
  • [26] Clinician's Guide to Prevention and Treatment of Osteoporosis
    Cosman, F.
    de Beur, S. J.
    LeBoff, M. S.
    Lewiecki, E. M.
    Tanner, B.
    Randall, S.
    Lindsay, R.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 (10) : 2359 - 2381
  • [27] History of alendronate
    Cummings, Steven R.
    Santora, Arthur C.
    Black, Dennis M.
    Russell, R. Graham G.
    [J]. BONE, 2020, 137
  • [28] Therapy of Osteoporosis in Men with Teriparatide
    Cusano, Natalie E.
    Costa, Aline G.
    Silva, Barbara C.
    Bilezikian, John P.
    [J]. JOURNAL OF OSTEOPOROSIS, 2011, 2011
  • [29] Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study
    Daly, Robin M.
    Gagnon, Claudia
    Lu, Zhong X.
    Magliano, Dianna J.
    Dunstan, David W.
    Sikaris, Ken A.
    Zimmet, Paul Z.
    Ebeling, Peter R.
    Shaw, Jonathan E.
    [J]. CLINICAL ENDOCRINOLOGY, 2012, 77 (01) : 26 - 35
  • [30] Esophagitis associated with the use of alendronate
    deGroen, PC
    Lubbe, DF
    Hirsch, LJ
    Daifotis, A
    Stephenson, W
    Freedholm, D
    PryorTillotson, S
    Seleznick, MJ
    Pinkas, H
    Wang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) : 1016 - 1021